AIM
FATE icon

Acrospire Investment Management’s Fate Therapeutics FATE Stock Holding History

Acrospire Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22
Closed – – 501
2017
Q2 		$0 Sell
22
-8,800
-100% -$33.7K ﹤0.01% 2267
2017
Q1 		$40K Sell
8,822
-13,288
-60% -$48.6K 0.03% 1133
2016
Q4 		$55K Buy
22,110
+18,036
+443% +$48.3K 0.02% 1336
2016
Q3 		$13K Sell
4,074
-66
-2% -$160 0.01% 1627
2016
Q2 		$7K Buy
+4,140
New +$7.51K 0.01% 1809

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Acrospire Investment Management's FATE Position: Q3 2017 in Review

Acrospire Investment Management sold out of Fate Therapeutics (FATE) in Q3 2017, closing a stake of 22 shares.

Acrospire Investment Management first reported a position in FATE in Q2 2016 and held it in 5 quarters. The position peaked at $55K in Q4 2016. 74 funds tracked by Wall St. Rank hold FATE as of Q3 2017.

  • Acrospire Investment Management reported no remaining Fate Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 22 Fate Therapeutics shares in Q3 2017.
  • Acrospire Investment Management first reported a position in Fate Therapeutics in Q2 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Fate Therapeutics position peaked at $55K in Q4 2016.
  • 74 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.